Adam D. Levy
CFO & Principal Financial OfficerDr. Adam D. Levy, PhD, MBA, is Chief Financial Officer and Principal Financial Officer of Acrivon Therapeutics, Inc. from April 1, 2025 and served as Senior VP and Head of Investor Relations & Corporate Affairs since July 2023 until April 1, 2025. He was Senior Vice President of Investor Relations of Zentalis Pharmaceuticals, Inc. from September 2022. He serves as Director for Vesselon Inc. Dr. Levy served as Senior Vice President of Investor Relations and Cooperate Communications at Turning Point Therapeutics, Inc. He served as Senior Vice President of Investor Relations at Turning Point Therapeutics, Inc. since November 08, 2021. He served as Executive Vice President of Corporate Development and Investor Relations at ZIOPHARM Oncology, Inc. since July 2021 until 2021 and also served as Executive Vice President of Investor Relations and Corporate Communications since November 2020 until July 2021. Most recently, Dr. Levy was Executive Director and Head, Corporate Strategy and Investor Relations for Gilead Sciences. Previously, Dr. Levy was VP, Corporate Strategy for Alexion and Executive Director, Corporate Strategy for Bristol-Myers Squibb. Dr. Levy had prior leadership positions with Novartis and McKinsey & Company. He holds a B.S. degree in Genetics from the University of Illinois at Urbana-Champaign. Dr. Levy holds a Ph.D. in Molecular Biology from the University of Illinois and an MBA in Finance and Strategy from Northwestern University Kellogg School of Management.
Positions
- Company NameAcrivon Therapeutics, Inc.Stock CodeACRVPositionCFO & Principal Financial OfficerColleagues
- PBPeter Blume-JensenCo-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
- KMKristina MassonCo-Founder, Executive VP of Business Operations, Site Head, Treasurer & Director
- EJEric J. DevroeChief Operating Officer
- KPKatharine PetersonVice President of Finance & Accounting
- JVJesper V. OlsenAcademic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board
- MJMichael John TomsicekIndependent Director
- CMCharles M. BaumIndependent Director
